|
Session 116-Poster Abstracts
Mechanisms of Activity and Failure of ART
Wednesday, 2-4 pm; Poster Hall |
589
 |
Genotypic Resistance at Viral Rebound in Antiretroviral-naive Subjects Randomized to Receive LPV/r or EFV-based Regimens in South Africa: A Substudy of the Phidisa II Trial
Judith Dlamini*1, Z Hu2, L Morris3, H Somaroo1, J Ledwaba3, F Maldarelli4, P Sangweni1, D Follmann2, R Dewar5, A Pau2, and Project PHIDISA
1Project PHIDISA, South Africa Military Hlth Svc, Pretoria; 2NIAID, NIH, Bethesda, MD, US; 3Natl Inst for Communicable Diseases, Johannesburg, South Africa; 4NCI, NIH, Bethesda, MD, US; and 5SAIC-Frederick, MD, US |
590
|
Estimation of Virological Residual Activity on a Regimen of Abacavir/Zidovudine/Lamivudine
David Dunn*1, D Pillay2, M Ranopa1, C Kityo3, P Munderi4, L Bacheler5, T Pattery6, A McCormick2, C Gilks7, P Kaleebu4, and DART Virology Group
1Med Res Council Clin Trials Unit, London, UK; 2Univ Coll London, UK; 3Joint Clin Res Ctr, Kampala, Uganda; 4Med Res Council/Uganda Virus Res Inst, Entebbe; 5VircoLab, Inc, Chapel Hill, NC, US; 6Virco BVBA, Mechelen, Belgium; and 7Imperial Coll London, UK |
591
|
Risk of Virological Failure of Antiretroviral Regimens including Nevirapine, Tenofovir, and Emtricitabine (or Lamivudine) in Previously Treated HIV-1-infected Patients
Josep Llibre*1, J Santos1, R Martin-Iguacel2, I Bravo1, C Caum1,3, N Perez-Alvarez1,3, and B Clotet1,4
1Fndn Lluita contra la SIDA, Hosp Germans Trias i Pujol, Badalona, Spain; 2Aarhus Univ Hosp, Aalborg, Denmark; 3Tech Univ of Catalonia, Barcelona, Spain; and 4Fndn irsiCaixa, Badalona, Spain |
592
|
High Frequency of Protease Drug Resistance Mutation among HIV--infected Patients Exposed to Second-line Antiretroviral Regimen in South India
Shanmugam Saravanan*1, V Madhavan1, S Solomon1, R Kantor2, S Solomon1, D Katzenstein3, B Ramratnam2, P Balakrishnan1, K Mayer2, and N Kumarasamy1
1YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India; 2Brown Univ, Providence, RI, US; and 3Stanford Univ, CA, US |
593
|
Bulk and Clonal Resistance Analyses in Highly Experienced Patients Failing Raltegravir-, Etravirine-, and Darunavir/ritonavir-containing Regimen (ANRS 139 TRIO Trial)
B Roquebert1, C Colin2, A-M Taburet3, C Fagard2, C Katlama4, J-M Molina5, C Jacomet6, G Chene2, Y Yazdanpanah7, Diane Descamps*1, and the ANRS139 TRIO Trial Study Group
1Univ Paris Diderot, Hosp Bichat Claude Bernard, Paris, France; 2INSERM U897, Bordeaux, France; 3Hosp Bicetre, Le Kremlin-Bicetre, France; 4Hosp Pitie-Salpetriere, Paris, France; 5Univ Paris Diderot, Hosp Saint Louis, Paris, France; 6Hosp Clermont-Ferrand, France; and 7Hosp Tourcoing, France |
|
